What Zepbound costs at every dose and through every channel: retail pens, LillyDirect vials, insurance, and the sleep apnea coverage route.
Zepbound costs about $1,086 per month at list price in 2026, but Eli Lilly sells it direct as single-dose vials through LillyDirect for $349 a month at 2.5 mg and $499 a month at 5 mg and above. With insurance coverage, copays run $25–$50; compounded tirzepatide, the same molecule, spans $199–$449.
Zepbound is the tirzepatide brand approved for weight loss, averaging 20.9% body weight reduction over 72 weeks in SURMOUNT-1, and uniquely among weight loss shots it carries a second indication, obstructive sleep apnea, that opens coverage doors the others cannot. Here is the price at every dose and channel, plus the annual totals.
Zepbound titrates from 2.5 mg to as high as 15 mg weekly. Price by dose and channel:
| Dose | Retail pens (list) | LillyDirect vials | Insured copay |
|---|---|---|---|
| 2.5 mg (starter) | ≈ $1,086 | $349 | $25–$50 |
| 5 mg | ≈ $1,086 | $499 | $25–$50 |
| 7.5 mg / 10 mg | ≈ $1,086 | $499 | $25–$50 |
| 12.5 mg / 15 mg | ≈ $1,086 | $499 | $25–$50 |
Pens price flat at list regardless of dose; vials have exactly two tiers. Compounded tirzepatide, not shown, typically scales from about $199 at entry doses toward $449 at the top.
Lilly's direct channel is the reason Zepbound's effective cash price is less than half its list. Single-dose vials, shipped, $349 for 2.5 mg, $499 for everything from 5 mg up, genuine FDA-approved tirzepatide with a syringe instead of the auto-injector pen.
Budget with the structure in mind: standard titration spends roughly four weeks at 2.5 mg, so the $349 rate is effectively a first-month price, and a realistic first year lands near $5,700. The program is self-pay only, cannot combine with insurance, and is HSA/FSA eligible with a prescription. Against compounded tirzepatide at $300–$449 for comparable maintenance doses, the brand premium shrinks to $50–$150 a month, a gap analyzed tier by tier in the cheapest tirzepatide ranking.
Logistics run through the program's pharmacy partner: prescriptions ship as sets of single-dose vials, refills renew monthly, and each weekly dose is drawn, injected, and its vial discarded. The single-dose format is the trade Lilly made for the lower price, no multi-dose handling and no measuring ambiguity beyond the draw itself, and it is part of why the vials are treated as the reference cash channel for this molecule rather than a compromise product.
Free online assessment · licensed providers · plans from $199/mo
Zepbound is FDA-approved not only for weight management but for moderate-to-severe obstructive sleep apnea in adults with obesity. That second indication changes insurance conversations, because plans that exclude "weight loss drugs", including Medicare, which does not cover weight loss alone, can still cover Zepbound when prescribed for diagnosed OSA.
If you have a sleep study documenting OSA, that diagnosis belongs at the center of the prior authorization, not as a footnote. The claim is being made for an approved indication, which puts it on far firmer ground than weight-loss exception requests. Prior auth mechanics, appeal language, and the medical necessity letter structure are all in the GLP-1 insurance guide. Insured copays, when approved, run $25–$50 a month, beating every cash tier.
The OSA route has one procedural difference worth anticipating: the documentation lives in sleep medicine, not weight management. Plans typically want the sleep study itself, its date and severity scoring, and often evidence about existing treatment such as positive airway pressure. Pulling those records before the prior authorization is filed, rather than during it, is the difference between a two-week approval and a two-month correspondence.
Twelve-month cost by path, assuming standard titration:
Context for the spend: SURMOUNT-1 measured 20.9% average body weight loss at 72 weeks, and the SURMOUNT-5 head-to-head put tirzepatide at 20.2% against semaglutide's 13.7%. Zepbound is the most effective approved option, priced, through the right channel, at or below what the less effective molecule's brand pens cost. Results vary individually, and eligibility, BMI 30-plus or 27 with a comorbidity, runs through a licensed provider.
Cost per unit of average result is where Zepbound's pricing stops looking premium. A year of vials at roughly $5,700 against a 20.9% trial average works out to less per average percentage point than brand semaglutide's $5,988 against 15%, and the retail-pen comparison is not close. Averages are not guarantees, but as a way to rank channels per dollar spent, the arithmetic consistently favors the vial program among brand options.
The three comparisons cash payers actually face:
A note on the pens themselves: for insured patients they remain the default, and nothing about the vial program changes a $25–$50 copay calculus. The vial-versus-pen question only exists for cash payers, where it is a $587-a-month question against list price, which is why the answer is nearly always the vial.
To put current numbers on the telehealth tier for your dose, compare tirzepatide program pricing here.
Free online assessment · licensed providers · plans from $199/mo
Zepbound Cost: The Dose-by-Dose Price Map
Take a free online assessment with a licensed provider — approval in minutes, medication delivered to your door.
Find Weight Loss Shots